PLDT Inc. Sponsored ADR (PHI)

SG&A Expenses

₱79.32B

TTM · Period ending: · PHP

PHI logo

PHI SG&A Expenses

Latest reported₱79.32B PHP
PHI TTM SG&A Expenses · PHP (₱0.00 → ₱79.32B)
High-resolution chart · PNG

PHI sg&a expenses history

Trailing twelve months (TTM) · PHP. Each value covers four complete reported quarters.

PLDT Inc. Sponsored ADR SG&A Expenses — Trailing twelve months (TTM) (PHP)
Period endingSG&A Expenses (PHP)
79,318,208,794
79,764,167,000
65,469,299,000
55,073,000,000
55,022,000,000
56,370,000,000
56,802,000,000
60,036,000,000
60,102,000,000
59,215,000,000
67,215,000,000
65,359,000,000
66,237,000,000
68,099,000,000
68,156,000,000
66,865,000,000
66,467,000,000
64,791,000,000
67,309,000,000
71,226,000,000
68,631,000,000
65,200,000,000
63,769,000,000
58,564,000,000
60,587,000,000
60,422,000,000
58,711,000,000
64,024,000,000
62,818,000,000
59,804,000,000
62,297,000,000
62,265,000,000
61,694,000,000
66,528,000,000
66,304,000,000
82,963,000,000
72,591,000,000
61,872,000,000
55,215,000,000
29,835,000,000
29,887,000,000
30,051,000,000
29,255,000,000
29,749,000,000
29,859,000,000
29,732,000,000
29,604,000,000
30,366,000,000
30,432,000,000
30,049,000,000
29,481,000,000
27,654,000,000
27,574,000,000
33,182,000,000
37,103,000,000
34,622,000,000
40,633,000,000
43,251,000,000
45,625,000,000
45,510,000,000
44,671,000,000
39,194,000,000
36,749,000,000
45,261,000,000
44,532,000,000
46,892,000,000
49,063,000,000
47,144,406,000
50,108,532,000
49,138,532,000
47,736,532,000
40,615,684,000
38,416,144,000
38,540,309,000
38,975,462,000
45,923,766,000
44,664,091,000
43,037,204,000
40,771,907,000
38,318,944,000
36,820,853,000
36,893,430,000
36,389,519,000
40,911,228,000
39,138,858,000
36,001,603,000
35,206,468,000
30,528,838,000
32,036,411,000
32,180,806,170
30,403,986,170
31,172,274,089
30,277,637,089
31,264,615,919
31,927,497,919
32,730,153,000
30,086,073,000
27,822,766,000
26,752,260,280
19,178,226,551
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.